Smith & Nephew SNATS (NYSE:SNN) Raised to Strong-Buy at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

SNN has been the topic of several other reports. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Canaccord Genuity Group raised their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday. Finally, Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $34.29 on Friday. The firm’s 50 day simple moving average is $34.43 and its 200-day simple moving average is $34.91. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a one year low of $23.91 and a one year high of $38.79.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Garner Asset Management Corp purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter worth about $27,000. Arax Advisory Partners boosted its position in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in Smith & Nephew SNATS in the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new position in Smith & Nephew SNATS during the 3rd quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Smith & Nephew SNATS during the 4th quarter worth approximately $43,000. 25.64% of the stock is owned by institutional investors and hedge funds.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.